Transforming Tremor Treatment using AI and Wearable Tech
When emerging technology is designed around real patient needs, it not only modernizes systems... it changes lives.
Today, Cala Health Founder Kate Rosenbluth and CEO Deanna Harshbarger join GOVTECH CONNECTS CEO Susan Sharer to explore how cutting-edge wearable technology transforms care for patients living with essential tremor.
Over 7 million Americans are affected by essential tremor — a progressive neurological condition that makes everyday tasks like eating, drinking, writing, or getting dressed incredibly difficult — treatment options have historically been limited to medications with significant side effects or invasive surgical procedures such as deep brain stimulation. Cala Health is working to change that.
We’ll explore how the latest in neuroscience research is applied to technology to provide dignity and independence to patients. It’s a compelling look at how scalable, wearable medical technology is driving measurable outcomes, restoring quality of life, and demonstrating how innovation can move from theory to implementation.
Find out more about the indications for use at calahealth.com/safety.
About Cala Health:
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its direct-to-home digital durable medical equipment (DME) platform is reshaping the delivery of prescription therapies. Cala Health’s Cala kIQ™ System with TAPS (Transcutaneous Afferent Patterned Stimulation) therapy is the only FDA-cleared, wearable device that delivers effective therapy for action hand tremor relief in people with essential tremor (ET) or Parkinson’s disease (PD). The TAPS device is physician-prescribed and clinically proven to safely and effectively manage action hand tremors.